LY2090314 is a GSK inhibitor which elevated Wnt signaling in melanoma cell lines.

<p><b>A</b>. Structure of LY2090314. <b>B</b>. Riluzole (<b>▲</b>), LY2090314 (■) and BIA (●) activated the TCF/LEF luminescent reporter in A375 cells following 5 hours of drug exposure. <b>C</b>. LY2090314 (20nM) decreased phosphorylation of GSK3α/β in A375 cells and increased β-catenin and Axin2 protein levels as determined by Western blot. <b>D</b>. LY2090314 (20nM) treatment of A375 cells increased Axin2 gene expression in a time dependent manor. <b>E</b>. Uncomplexed β-catenin IP experiments reveal a large increase in β-catenin protein following LY2090314 (20nM) treatment for 48 hours.